ATE415392T1 - Pyrimidinonderivate und deren verwendung bei der behandlung von atherosklerose - Google Patents
Pyrimidinonderivate und deren verwendung bei der behandlung von atheroskleroseInfo
- Publication number
- ATE415392T1 ATE415392T1 AT01986682T AT01986682T ATE415392T1 AT E415392 T1 ATE415392 T1 AT E415392T1 AT 01986682 T AT01986682 T AT 01986682T AT 01986682 T AT01986682 T AT 01986682T AT E415392 T1 ATE415392 T1 AT E415392T1
- Authority
- AT
- Austria
- Prior art keywords
- atherosclerosis
- treatment
- pyrimidinone derivatives
- pyrimidinone
- derivatives
- Prior art date
Links
- 201000001320 Atherosclerosis Diseases 0.000 title 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0024807.0A GB0024807D0 (en) | 2000-10-10 | 2000-10-10 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE415392T1 true ATE415392T1 (de) | 2008-12-15 |
Family
ID=9901005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01986682T ATE415392T1 (de) | 2000-10-10 | 2001-10-05 | Pyrimidinonderivate und deren verwendung bei der behandlung von atherosklerose |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7169924B2 (de) |
| EP (1) | EP1337517B1 (de) |
| JP (1) | JP2004511473A (de) |
| AR (1) | AR035068A1 (de) |
| AT (1) | ATE415392T1 (de) |
| AU (1) | AU2002223599A1 (de) |
| CA (1) | CA2459746A1 (de) |
| DE (1) | DE60136736D1 (de) |
| ES (1) | ES2317949T3 (de) |
| GB (1) | GB0024807D0 (de) |
| WO (1) | WO2002030911A1 (de) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60139429D1 (de) * | 2000-02-16 | 2009-09-10 | Smithkline Beecham Plc | Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren |
| GB0024807D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| GB0119793D0 (en) * | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
| GB0127140D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0127139D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0208280D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| GB0208279D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
| US7741020B2 (en) | 2004-04-16 | 2010-06-22 | Glaxo Group Limited | Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity |
| AU2006327314A1 (en) * | 2005-12-23 | 2007-06-28 | Astrazeneca Ab | Pyrazoles for the treatment of GERD and IBS |
| US20080090851A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
| US7705005B2 (en) * | 2006-10-13 | 2010-04-27 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
| US20080090852A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
| WO2008048867A2 (en) * | 2006-10-13 | 2008-04-24 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
| US8962633B2 (en) * | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| US9029383B2 (en) * | 2007-05-11 | 2015-05-12 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
| BRPI0721697A2 (pt) | 2007-05-11 | 2014-08-05 | Univ Jefferson | " métodos para tratar e/ou prevenir uma doença ou distúrbio neurodegenerativo em um indivíduo, para tratar e/ou prevenir um indivíduo com ou em risco de demência vascular, para tratar e/ou prevenir uma doença ou distúrbio associado com uma barreira hematoencefálica anormal em um indivíduo, para diminuir o acúmulo beta amilóide no cérebro de um indivíduo, para tratar e/ou prevenir mal de alzheimer em um indivíduo e para prevenir ou reduzir o risco de desenvolver mal de alzhheimer, e, uso de um agente que inibe a expressão e/ou atividade da proteína lp-pla2." |
| AU2011268127B2 (en) | 2010-06-18 | 2016-01-14 | Whitehead Institute For Biomedical Research | PLA2G16 as a target for antiviral compounds |
| US8637536B2 (en) | 2010-12-06 | 2014-01-28 | Glaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 |
| EP2651403B1 (de) | 2010-12-17 | 2020-12-02 | Glaxo Group Limited | Verwendung von lp-pla2-inhibitoren zur behandlung und vorbeugung von augenerkrankungen |
| WO2012129792A1 (zh) * | 2011-03-30 | 2012-10-04 | 中国科学院上海药物研究所 | 嘧啶酮类化合物、其制备方法及药物组合物和用途 |
| US20140171431A1 (en) | 2011-06-27 | 2014-06-19 | Jianhua Shen | Azole heterocyclic compound, preparation method, pharmaceutical composition and use |
| US9273054B2 (en) | 2011-07-27 | 2016-03-01 | Glaxo Group Limited | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors |
| EP2739627A4 (de) | 2011-07-27 | 2015-01-21 | Glaxo Group Ltd | 2,3-dihydroimidazo-[1,2-c-] pyrimidin-5 (1h)-on-verbindungen als lp-pla²- inhibitoren |
| FR2994184B1 (fr) * | 2012-08-02 | 2017-12-08 | Biomerieux Sa | Procedes de fonctionalisation et reactifs utilises dans de tels procedes utilisant un anhydride aza-isatoique ou un de ses derives, molecules biologiques ainsi traitees et kits |
| WO2014114694A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors |
| JP2016505053A (ja) | 2013-01-25 | 2016-02-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｌｐ‐ＰＬＡ２の阻害剤としての二環式ピリミドン化合物 |
| CA2899124A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
| WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| CN107709314A (zh) | 2015-06-11 | 2018-02-16 | 巴斯利尔药物国际股份公司 | 外排泵抑制剂及其治疗性用途 |
| CN111825695B (zh) * | 2019-04-15 | 2022-04-12 | 中国科学院上海药物研究所 | 噁唑烷酮类化合物、其制备方法、用途及其药物组合物 |
| US11591840B1 (en) * | 2019-10-31 | 2023-02-28 | Andersen Corporation | Power window operators, windows and methods |
| CN114805389B (zh) | 2019-11-09 | 2023-08-29 | 上海赛默罗生物科技有限公司 | 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| JP2026516205A (ja) | 2023-04-18 | 2026-05-20 | サイニューロ セラピューティクス インコーポレイテッド | Ｌｐ－ｐｌａ２阻害剤と第２の薬剤の併用治療 |
| CN118221687B (zh) | 2023-07-17 | 2024-12-31 | 上海枢境生物科技有限公司 | 双环[5,6]咪唑嘧啶酮类衍生物、其制备方法和应用 |
| WO2025024605A1 (en) * | 2023-07-25 | 2025-01-30 | University Of Florida Research Foundation, Incorporated | Rev-erb antagonists |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999024420A1 (en) * | 1997-11-06 | 1999-05-20 | Smithkline Beecham Plc | Pyrimidinone compounds and pharmaceutical compositions containing them |
| DE60139429D1 (de) * | 2000-02-16 | 2009-09-10 | Smithkline Beecham Plc | Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren |
| GB0024807D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| US6649610B1 (en) * | 2001-05-23 | 2003-11-18 | University Of Central Florida | 2-oxo-1, 4-benzoxazine compounds for treatment of tuberculosis |
-
2000
- 2000-10-10 GB GBGB0024807.0A patent/GB0024807D0/en not_active Ceased
-
2001
- 2001-10-05 AU AU2002223599A patent/AU2002223599A1/en not_active Abandoned
- 2001-10-05 WO PCT/EP2001/011562 patent/WO2002030911A1/en not_active Ceased
- 2001-10-05 CA CA002459746A patent/CA2459746A1/en not_active Abandoned
- 2001-10-05 JP JP2002534297A patent/JP2004511473A/ja active Pending
- 2001-10-05 EP EP01986682A patent/EP1337517B1/de not_active Expired - Lifetime
- 2001-10-05 US US10/398,977 patent/US7169924B2/en not_active Expired - Fee Related
- 2001-10-05 DE DE60136736T patent/DE60136736D1/de not_active Expired - Lifetime
- 2001-10-05 AT AT01986682T patent/ATE415392T1/de not_active IP Right Cessation
- 2001-10-05 ES ES01986682T patent/ES2317949T3/es not_active Expired - Lifetime
- 2001-10-10 AR ARP010104761A patent/AR035068A1/es unknown
-
2006
- 2006-07-07 US US11/456,129 patent/US7462620B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| GB0024807D0 (en) | 2000-11-22 |
| DE60136736D1 (de) | 2009-01-08 |
| ES2317949T3 (es) | 2009-05-01 |
| JP2004511473A (ja) | 2004-04-15 |
| CA2459746A1 (en) | 2002-04-18 |
| US20060241126A1 (en) | 2006-10-26 |
| AU2002223599A1 (en) | 2002-04-22 |
| EP1337517A1 (de) | 2003-08-27 |
| US20040058941A1 (en) | 2004-03-25 |
| US7462620B2 (en) | 2008-12-09 |
| WO2002030911A1 (en) | 2002-04-18 |
| EP1337517B1 (de) | 2008-11-26 |
| AR035068A1 (es) | 2004-04-14 |
| US7169924B2 (en) | 2007-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60136736D1 (de) | Pyrimidinonderivate und deren verwendung bei der behandlung von atherosklerose | |
| ATE374204T1 (de) | Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen | |
| DE60138768D1 (de) | Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln | |
| DE50009607D1 (de) | Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung | |
| ATE309224T1 (de) | Pyrimidin-2,4,6-trionen und deren verwendung als metalloproteinase inhibitoren | |
| DE60140377D1 (de) | Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit | |
| DE60133897D1 (de) | Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren | |
| DE60115870D1 (de) | Niedrig dosierte entecavir formulierung und deren verwendung | |
| DE60017894D1 (de) | Diaminothiazole und ihre verwendung zur inhibierung von proteinkinasen | |
| ATE349428T1 (de) | Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen | |
| DE60112791D1 (de) | Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität | |
| DE69826662D1 (de) | 4-brom or 4-iod-phenylamino-benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren | |
| ATE297380T1 (de) | Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit | |
| ATE384695T1 (de) | Carbamat caspase inhibitoren und deren verwendung | |
| ATE348805T1 (de) | 2-acyl-indolderivate und deren verwendung als antitumormittel | |
| DE60209486D1 (de) | Pyranoindazole und ihre verwendung in der glaukombehandlung | |
| DE60233265D1 (de) | 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten | |
| DE69823804D1 (de) | Azeotrope methoxyperfluorpropanzusammensetzungen und deren verwendung | |
| ATE375344T1 (de) | Azolotriazine und pyrimidine | |
| DE69915066D1 (de) | Biozide zusammensetzung und deren verwendung | |
| DE60010538D1 (de) | Kosmetische Tensid-Präparate und deren Verwendung | |
| ATE234840T1 (de) | 1-aminotriazolo 4,3-a chinazolin-5-one und/oder - thione inhibitoren von phosphodiesterasen iv | |
| EP1499186A4 (de) | Verwendung von häm-oxygenase-1 und häm-abbauprodukte | |
| DE60021507D1 (de) | Uracilverbindungen und deren Verwendung | |
| DE60017133D1 (de) | Naphthochinonderivate und ihre verwendung zur behandlung und kontrolle von tuberkulose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |